A detailed history of Van Hulzen Asset Management, LLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Van Hulzen Asset Management, LLC holds 71,172 shares of PCRX stock, worth $1.19 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
71,172
Previous 64,166 10.92%
Holding current value
$1.19 Million
Previous $1.84 Million 41.67%
% of portfolio
0.08%
Previous 0.12%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$11.7 - $28.46 $81,970 - $199,390
7,006 Added 10.92%
71,172 $1.07 Million
Q2 2024

Aug 07, 2024

BUY
$25.5 - $31.51 $759,492 - $938,493
29,784 Added 86.63%
64,166 $1.84 Million
Q1 2024

May 06, 2024

BUY
$27.7 - $35.48 $12,381 - $15,859
447 Added 1.32%
34,382 $1.01 Million
Q4 2023

Feb 07, 2024

BUY
$26.32 - $34.31 $60,378 - $78,707
2,294 Added 7.25%
33,935 $1.15 Million
Q3 2023

Nov 07, 2023

BUY
$30.68 - $40.09 $327,171 - $427,519
10,664 Added 50.84%
31,641 $971,000
Q2 2023

Aug 03, 2023

BUY
$36.12 - $47.5 $82,461 - $108,442
2,283 Added 12.21%
20,977 $841,000
Q1 2023

Apr 28, 2023

BUY
$35.53 - $43.38 $153,240 - $187,097
4,313 Added 29.99%
18,694 $763,000
Q4 2022

Feb 13, 2023

BUY
$38.19 - $57.45 $32,537 - $48,947
852 Added 6.3%
14,381 $555,000
Q3 2022

Nov 08, 2022

BUY
$51.24 - $58.89 $35,970 - $41,340
702 Added 5.47%
13,529 $720,000
Q2 2022

Aug 04, 2022

BUY
$51.49 - $81.64 $4,376 - $6,939
85 Added 0.67%
12,827 $748,000
Q1 2022

May 20, 2022

BUY
$60.03 - $76.49 $10,685 - $13,615
178 Added 1.42%
12,742 $972,000
Q4 2021

Feb 04, 2022

BUY
$47.97 - $62.21 $278,130 - $360,693
5,798 Added 85.69%
12,564 $756,000
Q3 2021

Nov 12, 2021

BUY
$54.64 - $61.3 $369,694 - $414,755
6,766 New
6,766 $379,000

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $769M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Van Hulzen Asset Management, LLC Portfolio

Follow Van Hulzen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Van Hulzen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Van Hulzen Asset Management, LLC with notifications on news.